NGS advances: Efficient fusion event detection in hematological malignancy clinical research

The SureSeq™ Myeloid Fusion Panel, crafted in collaboration with leading experts in myeloid cancer research to align seamlessly with the latest clinical guidelines, was used in this study. Harnessing RNA-based partner gene agnostic technology, our panel allows for simultaneous interrogation of multiple baited target fusions enhancing sample classification, including identification of novel and rare fusions.

Introduction

Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are both heterogeneous groups of hematological malignancies characterized by both phenotypic and genetic diversity, for which fusion genes are particularly prevalent¹. For example in AML, well-documented fusion events include RUNX1::RUNX1T1, CBFB::MYH11 and PML::RARA, as well as rearrangements involving KMT2A and NUP98².